Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy
ABSTRACT Background: Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality. Objective: The aim of treatment with antiseizure medications (ASMs) is to allow...
Saved in:
Published in | Arquivos de neuro-psiquiatria Vol. 79; no. 4; pp. 290 - 298 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English Portuguese |
Published |
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
Thieme Revinter Publicações Ltda
01.04.2021
Arquivos de Neuro-Psiquiatria Academia Brasileira de Neurologia - ABNEURO Academia Brasileira de Neurologia (ABNEURO) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | ABSTRACT
Background:
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
Objective:
The aim of treatment with antiseizure medications (ASMs) is to allow patients to remain without seizures, with good tolerability. Levetiracetam is a broad-spectrum ASM with a unique mechanism of action that differs it from other ASMs. It has been shown to be effective and safe for treating adults and children with epilepsy.
Methods:
This was a phase III, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of levetiracetam in children and adults (4-65 years) as an adjuvant treatment for focal-onset seizures. It was conducted among 114 patients undergoing treatment with up to three ASMs. The primary efficacy analysis was based on the proportion of patients who achieved a reduction of ≥ 50% in the mean number of focal seizures per week, over a 16-week treatment period. The patients were randomized to receive placebo or levetiracetam, titrated every two weeks from 20 mg/kg/day or 1,000 mg/day up to 60 mg/kg/day or 3,000 mg/day.
Results:
Levetiracetam was significantly superior to placebo (p = 0.0031); 38.7% of the participants in the levetiracetam group and 14.3% in the control group shows reductions in focal seizures. Levetiracetam was seen to have a favorable safety profile and an adverse event rate similar to that of placebo.
Conclusion:
Corroborating the results in the literature, levetiracetam was shown to be effective and safe for children and adults with refractory focal-onset epilepsy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Authors’ contributions: All authors participated in the preparation and review of the article and were responsible for the submission. Conflict of interest: The author is an employee of Aché Laboratórios Farmacêuticos S.A., sponsor of the study. |
ISSN: | 0004-282X 1678-4227 1678-4227 |
DOI: | 10.1590/0004-282X-ANP-2020-0082 |